cardiovasculardiseaseq2yhormonetherapyraloxifene40y.o.community-dwelling,postmenopausalwomenanxiety≥ 140mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors< 60y.o.≥5.7%Timedup andgo testinsufficientevidenceforscreeningmultidoseinitial series,then 1 doseat 2-6monthsFractureRiskAssessmentTool≥ 100mg/dLq1ymammogram65y.o.herpeszoster≥ 126mg/dL≥6.5%hypertensionPREVENTequationwomenage 55-64 y.o.tobaccouse75y.o.colorectalcancerlungcancer40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factortamoxifen≤q2yGailmodelbreastcancerq3y40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorovariancancercervicalcancerq1yaromataseinhibitors40-59 y.o.,ASCVD ≥10%, lowbleeding risk40-70 y.o.,ASCVD ≥10%, lowbleeding risk≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors60y.o.1 dose; 2doses (2-6monthsapart) ifimmunocompHepatitisC52y.o.≥20%≥ 200mg/dLHepatitisB2 doses,2-6monthsapartq15ydepressiondyslipidemiadiabetesHIV3%q1-2ymammogrambased on lifeexpectancy /health statuspneumococcaldementia50y.o.Tyrer-Cuzickmodelq5yoverweight/ obesityaspirinstatincardiovasculardiseaseq2yhormonetherapyraloxifene40y.o.community-dwelling,postmenopausalwomenanxiety≥ 140mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors< 60y.o.≥5.7%Timedup andgo testinsufficientevidenceforscreeningmultidoseinitial series,then 1 doseat 2-6monthsFractureRiskAssessmentTool≥ 100mg/dLq1ymammogram65y.o.herpeszoster≥ 126mg/dL≥6.5%hypertensionPREVENTequationwomenage 55-64 y.o.tobaccouse75y.o.colorectalcancerlungcancer40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factortamoxifen≤q2yGailmodelbreastcancerq3y40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorovariancancercervicalcancerq1yaromataseinhibitors40-59 y.o.,ASCVD ≥10%, lowbleeding risk40-70 y.o.,ASCVD ≥10%, lowbleeding risk≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors60y.o.1 dose; 2doses (2-6monthsapart) ifimmunocompHepatitisC52y.o.≥20%≥ 200mg/dLHepatitisB2 doses,2-6monthsapartq15ydepressiondyslipidemiadiabetesHIV3%q1-2ymammogrambased on lifeexpectancy /health statuspneumococcaldementia50y.o.Tyrer-Cuzickmodelq5yoverweight/ obesityaspirinstatin

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. cardiovascular disease
  2. q2y
  3. hormone therapy
  4. raloxifene
  5. 40 y.o.
  6. community-dwelling, postmenopausal women
  7. anxiety
  8. ≥ 140 mg/dL
  9. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  10. < 60 y.o.
  11. ≥ 5.7%
  12. Timed up and go test
  13. insufficient evidence for screening
  14. multidose initial series, then 1 dose at 2-6 months
  15. Fracture Risk Assessment Tool
  16. ≥ 100 mg/dL
  17. q1y mammogram
  18. 65 y.o.
  19. herpes zoster
  20. ≥ 126 mg/dL
  21. ≥ 6.5%
  22. hypertension
  23. PREVENT equation
  24. women age 55-64 y.o.
  25. tobacco use
  26. 75 y.o.
  27. colorectal cancer
  28. lung cancer
  29. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  30. tamoxifen
  31. ≤ q2y
  32. Gail model
  33. breast cancer
  34. q3y
  35. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  36. ovarian cancer
  37. cervical cancer
  38. q1y
  39. aromatase inhibitors
  40. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  41. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  42. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  43. 60 y.o.
  44. 1 dose; 2 doses (2-6 months apart) if immunocomp
  45. Hepatitis C
  46. 52 y.o.
  47. ≥ 20%
  48. ≥ 200 mg/dL
  49. Hepatitis B
  50. 2 doses, 2-6 months apart
  51. q15y
  52. depression
  53. dyslipidemia
  54. diabetes
  55. HIV
  56. 3%
  57. q1-2y mammogram based on life expectancy / health status
  58. pneumococcal
  59. dementia
  60. 50 y.o.
  61. Tyrer-Cuzick model
  62. q5y
  63. overweight / obesity
  64. aspirin
  65. statin